Key Highlights
- Silence Therapeutics (NASDAQ:SLN) closed at USD 19.76 on November 5, 2026, up 95.21% in one month, 65.18% over three months, 188.39% over six months and 219.14% year to date, with a session change of minus 0.23%.
- The 1M gain ranks third among 1,259 small cap names (market cap 300 million to 2 billion USD) in a published screener snapshot, and the 1W gain was 0.23%.
- The Phase 2 SANRECO trial of divesiran in polycythemia vera met its primary endpoint on August 10, 2026: an 88% clinical response against 19% for placebo, and the stock rose 35.3% that day.
- Cash was USD 72.1 million at June 30, 2026, the quarterly net loss narrowed to USD 12.3 million from USD 27.4 million, and 141,739,180 ordinary shares were outstanding.
What Moved Silence Therapeutics (1M +95.21%)
The 1M gain implies a price near USD 10.12 a month ago, by simple arithmetic. Silence Therapeutics (NASDAQ:SLN) was flat in the latest week, up 0.23%, and down 0.23% on the session. No single catalyst for the past month was identified in the material reviewed. The main fundamental event is the August 10, 2026 topline readout, which fits inside the 3M and 6M windows: every six weeks dosing gave a 93.8% response, every twelve weeks gave 81.3%, and mean phlebotomies per patient were 0.2 against 2.1 for placebo, with no new safety findings. The trial enrolled 48 phlebotomy-dependent patients.
Why a Stock Like This Re-Rates
Clinical data are the usual driver for a biotech. A randomized, placebo-controlled win in a rare blood disease lifts the probability of approval, brings a Phase 3 trial into view, and raises partnering interest. The company plans to start a Phase 3 quarterly dosing study in the first half of 2027 and potential IND filings for SLN365 and SLN098 in 2027. A partnered program, SLN312 with AstraZeneca, showed dose-dependent ANGPTL3 reductions in Phase 1. Cantor Fitzgerald rated the stock Overweight on June 24, 2026, and HC Wainwright rated it Buy on March 13, 2026. Momentum buyers and sector rotation into biotech may have added to the move; that is general context.
Valuation, Liquidity and Risks After a 95% Run
The stock is up 219.14% year to date and 188.39% over six months, so the latest 95.21% month extends an already large run. Research and Development expense fell to USD 9.1 million from USD 17.6 million in the second quarter, and general and administrative expense was USD 4.7 million. Revenue was zero in the quarter against USD 224 thousand a year ago, and no cash runway figure was given. Cash of USD 72.1 million against a six month net loss of USD 27.2 million leaves limited Margin before a Phase 3 trial, so an Equity raise is a risk. As a small cap, trading can be thin, spreads wide and a few trades can move the price.
Where Things Stand
The gain appears driven by the divesiran Phase 2 data and sustained momentum, with no new single catalyst found for the latest month. Silence Therapeutics (NASDAQ:SLN) sits at number three on the small cap 1M leaderboard of 1,259 names, behind Bumble at 132.88% and Katapult at 113.46%. At USD 19.76, the shares price in much success; Phase 3 start, financing and trial execution are the next tests.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...